Comparison of neurotropic and antioxidant activity of Cytoflavin and etilmetilgydroxypiridine succinat in patients with chronic brain ischemia

Kataeva N.G.; Zamoshchina T.A.; Svetlik M.V.; Korotkova E.I.; Voronova O.A.

doi:https://doi.org/10.17116/jnevro202212211198

Kataeva N.G.

Siberian State Medical University

Zamoshchina T.A.

Siberian State Medical University;
National Research Tomsk State University

Svetlik M.V.

Siberian State Medical University;
National Research Tomsk State University

Korotkova E.I.

National Research Tomsk Polytechnic University

Voronova O.A.

National Research Tomsk Polytechnic University

Comparison of neurotropic and antioxidant activity of Cytoflavin and etilmetilgydroxypiridine succinat in patients with chronic brain ischemia

Authors:

Kataeva N.G., Zamoshchina T.A., Svetlik M.V., Korotkova E.I., Voronova O.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(11): 98‑104

DOI: 10.17116/jnevro202212211198

Read: 8392 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Kataeva NG, Zamoshchina TA, Svetlik MV, Korotkova EI, Voronova OA. Comparison of neurotropic and antioxidant activity of Cytoflavin and etilmetilgydroxypiridine succinat in patients with chronic brain ischemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(11):98‑104. (In Russ.)
https://doi.org/10.17116/jnevro202212211198

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

Determination of the total antioxidant activity of blood serum (AOA) of patients with chronic cerebral ischemia (CCI) I—II st. against the background of treatment with Cytoflavin or ethylmethylhydroxypyridine succinate (EMGPS) and evaluation of the effect of drugs on the state of cognitive functions and emotional sphere of patients.

MATERIAL AND METHODS

The main group consisted of 12 women with CCI I—II st., treated on an outpatient basis with Cytoflavin 1 tablet 2 times/day as part of complex therapy for 1 month; 12 patients with CCI I—II st., treated as part of complex therapy with EMGPS 125 mg 2 times/day for 1 month we made a comparison group. The groups are comparable in age, gender, the nature of risk factors, the severity of neurological manifestations, and the nature of basic therapy. The state of AOA, the severity and nature of cognitive and emotional disorders were assessed.

RESULTS

It was found that the inclusion of Cytoflavin or EMGPS in complex therapy equally increased the AOA of patients. The decrease in the severity of neurological deficit during treatment consisted in improving spatio-temporal gnosis by improving the relationships in the cortex and synchronizing the activity of its different departments with the rate of nervous activity and neurophysiological characteristics different for each drug. The use of both drugs led to a decrease in the selection reaction time and the number of errors in recognizing the angular velocity of movement. Cytoflavin increased the selectivity of perception and attention in patients, while EMGPS did not affect this indicator.

CONCLUSION

The use of Cytoflavin and EMGPS leads to an increase in AOA, has various effects on the cognitive functions of patients with CCI.

Keywords:

chronic cerebral ischemia

Cytoflavin

ethylmethylhydroxypyridine succinate

Authors:

Kataeva N.G.

Siberian State Medical University

Zamoshchina T.A.

Siberian State Medical University;
National Research Tomsk State University

Svetlik M.V.

Siberian State Medical University;
National Research Tomsk State University

Korotkova E.I.

National Research Tomsk Polytechnic University

Voronova O.A.

National Research Tomsk Polytechnic University

Received:

06.10.2022

Accepted:

20.10.2022

Close metadata

References:

Suslina ZA, Rumiantseva SA, Tanashyan MM, et al. Complex energy correction in chronic cerebral ischemia. Neurosci Behav Physiol. 2012;42(6):537-542. https://doi.org/10.1007/s11055-012-9597-8
Kostenko EV, Petrova LV. Pathophysiological features of chronic cerebrovascular diseases and possibilities of complex neuroprotective therapy. Medical Council. 2019;1:24-30. (In Russ.). https://doi.org/10.21518/2079-701X-2019-1-24-30
Kearney-Schwartz A, Rossignol P, Bracard S. Vascular structure and function is corre-lated to cognitive performance and white matter hyperintensities in older hypertensive pa-tients with subjective memory complaints. Stroke. 2009;40:1229-1236. https://doi.org/10.1161/strokeaha.108.532853
Antipenko EA, Derugina AV, Gustov AV. The system stress-limiting action of mexidol in chronic cerebral ischemia. Zhurnal nevrologii i Psihiatrii im. S.S. Korsakova. 2016;116(4):28-31. (In Russ.). https://doi.org/10.17116/jnevro20161164128-31
Shakhparonova NV, Kadykov AS. Chronic vascular diseases of the brain: an algorithm for diagnosis and treatment. Consilium Medicum. 2017;2(19):104-109. (In Russ.).
Zakharov VV, Vakhnina NV. Practical algorithms for managing patients with cognitive impairments. Medical Council. 2019;6:27-33. (In Russ.). https://doi.org./10.21518/2079-701x-2019-6-27-33
Zhivolupov SA, Butakova YuS, Samartsev IN. Contemporary paradigm of rational stroke treatment. Zhurnal nevrologii i Psihiatrii im. S.S. Korsakova. 2016;8(2):82-87. (In Russ.). https://doi.org/10.17116/jnevro20161168282-87
Mezhdunarodnaya klassifikatsiya boleznei (10 peresmotr). Klassifikatsiya psikhicheskikh i povedencheskikh rasstroistv. SPb.: Overlaid; 1994;61-68:111-130. (In Russ.).
Solovieva EYu, Chipova DT. From the conception of «oxidizing stress» to the conception of cell signaling modulation. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2015;115(8):105-111. (In Russ.). https://doi.org/10.17116/jnevro201511581105-111
Voronina TA. The role of hypoxia in stroke and convulsive states. Antihypoxants. Reviews on Clinical Pharmacology and Drug Therapy. 2016;14(1):63-70. (In Russ.). https://doi.org/10.17816/RCF14163-70
Chukanova EI, Chukanova AS, Mamaeva HI. The results of the study of the efficacy and safety of Mexidol in patients with chronic brain ischemia. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2015;115(2):71-74. (In Russ.). https://doi.org/10.17116/jnevro20151152171-74
Chutko LS, Surushkina SY, Yakovenko EA, et al. Efficiency of cytoflavin in the treatment of somatoform disorders. Zhurn. Nevrol. i Psihiatrii im. S.S. Korsakova. 2017;117(1):21-24. (In Russ.). https://doi.org/10.17116/jnevro20171171121-24
Mazin PV, Sheshunov IV, Mazina NK. Meta-analytic assessment of parenteral cytoflavin effectiveness in different neurologic disorders. S.S. Korsakova Zhurn Nevrol Psihiat. 2017;3:28-39. (In Russ.). https://doi.org/10.17116/jnevro20171173128-39
Platov MP, Kosivtsova OV. Headache in elderly patients with chronic cerebral ischemia: outpatient diagnosis and treatment. Neurology, Neuropsychiatry, Psychosomatics. 2018;10(1):102-106. (In Russ.). https://doi.org/10.14412/2074-2711-2018-1-102-106
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatrica Scand. 1983;67(6):361-370. https://doi.org/10.1111/j.1600-0447.1983.tb09716.x
Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a Frontal Assessment Battery at bedside. Neurology. 2000;55(11):1621-1626. https://doi.org/10.1212/wnl.55.11.1621
Koryagina YuV, Nopin SV. Issledovatel’ vremennykh i rostranstvennykh svoistv cheloveka. Patent RF №2004610221. Programmy dlya EVM. Ofits. byull. 2004;2(47):51. (In Russ.).
Korotkova EI, Freinbichler W, Linert W, et al. Study of total antioxidant activity of human serum blood in the pathology of alcoholism. Molecules. 2013;18(2):1811-1818. https://doi.org/10.3390/molecules18021811
Plotnikov E, Korotkova E, Voronova O, et al. Comparative investigation of antioxidant activity of hu-man serum blood by amperometric, voltammetric and chemiluminescent methods. Archives of medical science. 2016;12(5):1071-1076.
Chukanova EI, Chukanova AS. Efficacy and safety of the drug mexidol FORTE 250 as part of sequential therapy in patients with chronic ischemia of the brain. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2019;119(9):39-45. (In Russ.). https://doi.org/10.17116/jnevro201911909139
Dorovskikh VA, Simonova NV, Pereverzev DI, Shtarberg MA. Comparative effectiveness of cytoflavin and its constituent components in experimental oxidative stress. Experimental and clinical pharmacology. 2017;80(4):18-22. (In Russ.). https://doi.org/10.30906/0869-2092-2017-80-4-18-22
Goroshko OA, Checha OA, Demchenkova EU. Ability of cytoflavin to influence on antioxigen system of the organism protection. Biomed. 2011;1(4):71-72. (In Russ).
Berezhnaya SV, Iakupov ÉZ, Zaharov YuA. The efficacy of combination therapy with mexidol and cerebrolysin in chronic cerebral ischemia. S.S. Korsakov Journal of Neurology and Psychiatry = Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2016;116(5):23-27. (In Russ.). https://doi.org/10.17116/jnevro20161165123-27
Zhelnov VV, Petrovskaya NV, Komarova IS. Sovremennye podkhody k kombinirovannoi terapii arterial’noi gipertonii. RMZh. Kardiologia. 2007;28:2138-2142. (In Russ.).
Sychev DA, Otdelenov VA, Krasnova NM, Ilyina ES. Polypragmasy: A clinical pharmacologist’s view. Terapeuticheskij arkhiv. 2016;88(12):94-102. (In Russ.). https://doi.org/10.17116/terarkh2016881294-102